ALNYLAM PHARMACEUTICALS, INC.

ALNY

Explore Our Financial Data > Companies > ALNYLAM PHARMACEUTICALS, INC.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
ALNY
CIK0001178670
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
Website alnylam.com
Phone(617) 551-8200
CEOYvonne L. Greenstreet
Employees2,000

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$2.46 billion
Pre-Tax Income$-379.58 million
Net Income$-319.09 million
Net Income to Common$-319.09 million
EPS$-2.48
View All
Balance Sheet
Cash$1.11 billion
Assets$4.57 billion
Liabilities$4.32 billion
Common Equity$250.59 million
Liabilities & Equity$4.57 billion
View All
Cash Flow Statement
Net Income$-319.09 million
Cash From Operating Activities$-15.54 million
Cash From Investing Activities$-110.77 million
Cash From Financing Activities$231.59 million
Change in Cash$144.67 million
View All
Calculations
NOPAT$-126.13 million
EBITDA$-290.16 million
Price to EarningsN/A
Price to Book$210.17
ROE-257.82%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Alnylam (ALNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Alnylam (ALNY) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Article Link

Alnylam reaches new highs on strong sales of closely watched rare disease drug

Despite battling drugs from BridgeBio and Pfizer, Amvuttra beat Wall Street expectations with results Alnylam’s CEO claimed were “not a flash in the pan.”

Article Link

Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of +1,166.67% and +14.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Article Link

Alnylam: Q2 Earnings Snapshot

CAMBRIDGE, Mass. AP) — Alnylam Pharmaceuticals Inc. ALNY) on Thursday reported a loss of $66.3 million in its second quarter.

Article Link

Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress

CAMBRIDGE, Mass., July 31, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2025 and reviewed recent business highlights.

Article Link